HDL Therapeutics is a company that develops medical devices for the treatment of coronary atherosclerosis. It offers PDS-2 System, a therapeutic device that transforms a patient’s own plasma into an atherosclerosis reversal agent for the regression of plaque in coronary arteries of patients with Homozygous Familial Hypercholesterolemia (HoFH).